Reoperation for multivalvular prosthetic valve infective endocarditis: successful urgent surgical management of severe mitral and aortic insufficiency: a case report
DOI:
https://doi.org/10.66636/gmj.v1.i3.a199Keywords:
infective endocarditis, prosthetic valve endocarditis, multivalvular endocarditis, Staphylococcus aureus, double-valve replacement, reoperation, cardiac surgery, Duke criteria, case reportAbstract
Background: Infective endocarditis (IE) remains a life-threatening condition with in-hospital mortality of 15–30%, rising substantially in multivalvular disease. Prosthetic valve endocarditis (PVE) following cardiac surgery carries additional operative risk due to the requirement for complete prosthetic debridement. We report a case of multivalvular PVE with large mobile mitral vegetations, Staphylococcus aureus bacteraemia, and multifocal systemic embolisation requiring urgent reoperation.
Case presentation: A 69-year-old male with prior mitral annuloplasty presented with progressive heart failure, recurrent fever, and embolic cerebral and splenic infarcts. Echocardiography demonstrated large mobile mitral vegetations with severe mitral regurgitation (MR grade III–IV) and significant aortic regurgitation (AR grade III–IV). Blood cultures yielded Staphylococcus aureus. The diagnosis of definite IE was confirmed by 2023 ESC Duke-modified criteria. Urgent reoperation was performed: complete excision of the infected annuloplasty ring, radical debridement of all vegetations, and biological double-valve replacement. Cardiopulmonary bypass time was 185 minutes; cross-clamp time 135 minutes. Four weeks of targeted vancomycin therapy were administered postoperatively. The patient was discharged in stable condition with normalised inflammatory markers and satisfactory prosthetic function on echocardiography.
Conclusion: Multivalvular PVE requires prompt echocardiographic diagnosis, urgent surgical intervention with complete prosthetic debridement, and extended targeted antimicrobial therapy. A multidisciplinary Endocarditis Team approach is essential for optimal outcomes in this high-risk population.
Keywords: infective endocarditis; prosthetic valve endocarditis; multivalvular endocarditis; Staphylococcus aureus; double-valve replacement; reoperation; cardiac surgery; Duke criteria; case report
References
1. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG. Infective endocarditis. Nat Rev Dis Primers. 2016;2:16059. https://doi.org/10.1038/nrdp.2016.59
2. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016;387(10021):882-893. https://doi.org/10.1016/S0140-6736(15)00067-7
3. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. https://doi.org/10.1093/eurheartj/ehad193
4. Imazio M. The 2023 new European guidelines on infective endocarditis: main novelties and implications for clinical practice. J Cardiovasc Med (Hagerstown). 2024;25(10):718-726. https://doi.org/10.2459/JCM.0000000000001651
5. Kyriakoulis IG, Kyriakoulis KG, Pennisi M, Skaltsas S, Giordano A, Anastasio F, et al. Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis. Future Cardiol. 2025;21(2):113-121. https://doi.org/10.1080/14796678.2025.2457898
6. Oldberg K, Rasmussen M. Make Modern Microbiology Matter More in the 2023 European Society of Cardiology Guidelines for the Management of Infective Endocarditis. Clin Infect Dis. 2024;79(2):336-338. https://doi.org/10.1093/cid/ciae222
7. de Waha S, Sandri M, Schroter T, Mohr FW, Thiele H, Holzhey D. ESC guidelines 2023 on the management of endocarditis: What is new? Herz. 2024;49(1):33-42. https://doi.org/10.1007/s00059-023-05225-y
8. de la Cuesta M, Centeno J, Cuenca-Castillo JJ, Badia JL, Bernal JM, Garrido-Bravo IP, et al. Surgical implications of the 2023 ESC Endocarditis Guidelines endorsed by EACTS: Bridging guidelines and practice. Eur J Cardiothorac Surg. 2025;67(7). https://doi.org/10.1093/ejcts/ezaf225
9. Le Moing V, Duval X, Entenza JM, Huttner A, SPILF-AEPEI Working Group. Antibiotic therapy and prophylaxis of infective endocarditis -- A SPILF-AEPEI position statement on the ESC 2023 guidelines. Infect Dis Now. 2025;55(1):105011. https://doi.org/10.1016/j.idnow.2024.105011
10. Mohananey D, Mohadjer A, Pettersson G, Navia JL, Gillinov M, Gordon S, et al. Association of vegetation size with embolic risk in patients with infective endocarditis. JAMA Intern Med. 2018;178(4):502-510. https://doi.org/10.1001/jamainternmed.2017.8653
11. Maher P, Mullan B, Sharif H, Ruttledge S. The endocarditis team: a review. Expert Rev Anti Infect Ther. 2026;1-12. https://doi.org/10.1080/14787210.2026.2695437
12. Meena DS, Rohila R, Mishra K, Singla M, Choudhary N, Jakhar M. Impact of methicillin resistance on mortality in Staphylococcus aureus endocarditis: a systematic review and meta-analysis. Commun Med (Lond). 2026. https://doi.org/10.1038/s43856-026-01746-9
13. Goehringer F, Camou F, Chirouze C, Delahaye F, Botelho-Nevers E, Nazeyrollas P, et al. Compared performance of the 2023 Duke-ISCVID, 2000 Modified Duke, and 2015 ESC criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2024;78:937-948. https://doi.org/10.1093/cid/ciae035
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Giorgi Gabaidze, Medea Kadjaia, Bachuki Nachkebia, Khatia Kontselidze, Qristina Qiqava, Anano Kobaladze, Keti Beridze, Keti Dumbadze, Dea Kotrikadze
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
You are free to: share and adapt the work for any purpose, even commercially.
Conditions: provide appropriate credit to the authors and the Georgian Medical Journal (GMJ), link to the licence, and indicate if changes were made. Do not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.
Licence: creativecommons.org/licenses/by/4.0 · Legal code: creativecommons.org/licenses/by/4.0/legalcode
Third-party material. Images or other content credited to a third party are not covered by CC BY 4.0; permission must be obtained from the rights holder for reuse beyond statutory exceptions.
Authors' rights. Authors retain copyright. First publication rights are granted to GMJ.
Data and code. Where provided, datasets or code may carry their own licences; please follow the licence stated in the article or repository record.
Listen on Spotify
Apple Podcasts
YouTube
Amazon Music
Castbox
Pocket Casts
LinkedIn
Facebook
X
Instagram
Substack
Bluesky
ResearchGate
